InsiderTrades.com logo
Joshua Cohen net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joshua Cohen Biography and Net Worth

Co-Founder of Amylyx Pharmaceuticals
Josh Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served since that time as its Co-CEO and Co-Founder. Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly $250M in financing to support the development of new therapies for ALS and other neurodegenerative diseases. Josh received his Bachelor of Science in Biomedical Engineering from Brown University.

How old is Joshua Cohen?

Mr. Cohen is currently 32 years old. There are 4 older executives and no younger executives at Amylyx Pharmaceuticals. The oldest executive at Amylyx Pharmaceuticals is Dr. Camille L. Bedrosian M.D., Chief Medical Officer, who is 71 years old. Learn More on Joshua Cohen's age.

How do I contact Joshua Cohen?

The corporate mailing address for Mr. Cohen and other Amylyx Pharmaceuticals executives is , , . Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on Joshua Cohen's contact information.

Has Joshua Cohen been buying or selling shares of Amylyx Pharmaceuticals?

Joshua Cohen has not been actively trading shares of Amylyx Pharmaceuticals during the last ninety days. Learn More on Joshua Cohen's trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $37,000.00. In the last year, insiders at the sold shares 13 times. They sold a total of 169,893 shares worth more than $1,666,686.16. The most recent insider tranaction occured on December, 1st when insider Camille L Bedrosian sold 6,580 shares worth more than $94,423.00. Insiders at Amylyx Pharmaceuticals own 12.3% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 12/1/2025.

Joshua Cohen Insider Trading History at Amylyx Pharmaceuticals

See Full Table

Joshua Cohen Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows Mr. Joshua Cohen's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.49
Low: $13.91
High: $14.64

50 Day Range

MA: $14.00
Low: $12.18
High: $15.79

2 Week Range

Now: $14.49
Low: $2.60
High: $16.96

Volume

781,740 shs

Average Volume

1,403,731 shs

Market Capitalization

$1.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A